Telesis Bio Inc
NASDAQ:TBIO
Net Margin
Telesis Bio Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Telesis Bio Inc
NASDAQ:TBIO
|
177.3k USD |
-354%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
151.1B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.5B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
70.6T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.2B CHF |
10%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
6.8T JPY |
-5%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.8B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.1B USD |
9%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
188.5B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.9B USD |
22%
|
Telesis Bio Inc
Glance View
Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Telesis Bio Inc's most recent financial statements, the company has Net Margin of -354.1%.
You don't have any saved screeners yet